Loading...

MIRM MIRUM PHARMACEUTICALS INC Legal Disputes 8-K Filing

MRM

MRM

MIRUM PHARMACEUTICALS INC

(MIRM)

2025 8-K

Financial Results Released

Study Results Announced

Brelovitug Study Results

Acquisition Update

Financial Results Update

Merger Completed

Earnings Update

Patent Infringement Lawsuit

Investment Agreement

Merger Announcement

Patent Challenge Notice

Corporate Update

Financial Statements

Financial Results

Financial Results

Earnings Reports

Interim Results of Volixiba...

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

Management Promotion

Financial Results Announcement

Results Announcement

Acquisition and Private Pla...

FDA Review Extension

Appointment of CFO

Earnings Reports

Acquisition of Assets

Annual Meeting Results

Earnings Reports

Issuance of Convertible Sen...

Financial Results and Busin...

Appointment and Resignation

Closure of Silicon Valley Bank

Earnings Reports

Earnings Reports

External Links:

On November 17, 2025, Mirum Pharmaceuticals, Inc. received a Paragraph IV Certification Notice Letter from Sandoz, Inc. regarding a generic version of their drug Livmarli®, claiming invalidity of several related patents; Mirum intends to file a patent infringement lawsuit to protect its rights.

AI Assistant

MIRUM PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.